Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Mais filtros

Base de dados
Ano de publicação
Tipo de documento
Intervalo de ano de publicação
1.
Front Vet Sci ; 9: 1053005, 2022.
Artigo em Inglês | MEDLINE | ID: mdl-36619961

RESUMO

The use of palm kernel cake as an alternative to conventional ingredients, due to the presence of residual fat, can also reduce methane emissions. The objective of the study was to evaluate, in two different experiments, the effects of palm kernel cake supplementation on feed intake, enteric methane production and estimates, and the ingestive behavior of buffaloes in the Amazon biome. In experiment 1, to evaluate feed intake, methane production, and feed efficiency, 20 crossbred females, dry and empty, with a mean age of 34 months and an initial body weight of 514 ± 69 kg, were supplemented with palm kernel cake for 60 days. The supply was calculated in relation to body weight (BW) in four treatments: 0% (control); 0.25, 0.50, and 1% of palm kernel cake, distributed in a completely randomized design. In experiment 2, to evaluate the ingestive behavior, 24 mixed-breed, dry, and non-pregnant buffaloes supplemented with palm kernel cake were evaluated in the less rainy season (LR) and the wettest season (WS) of the eastern Amazon, distributed in a completely randomized in the same treatments as experiment 1. The inclusion of palm kernel cake in the supplementation increased the feed intake of dry matter and components (MM, OM, CP, NDF, ADF, and EE) (P < 0.01), reducing the production of enteric methane intake (P < 0.01), the ratio per kg of meat produced (P < 0.01) and feed efficiency (P < 0.01), and influenced the ingestive behavior (time grazing, rumination, and idleness) during the day. We suggest that further research be carried out to verify the results and improve the use of this co-product as a methanogenesis mitigator.

2.
Cancer Chemother Pharmacol ; 88(5): 837-844, 2021 11.
Artigo em Inglês | MEDLINE | ID: mdl-34331561

RESUMO

PURPOSE: Fluoropyrimidines are one of the most used drug class to treat cancer patients, although they show high levels of associated toxicity. This study analyzed 33 polymorphisms in 17 pharmacogenes involved with the pharmacogenomics of fluoropyrimidines, in gastrointestinal cancer patients undergoing fluoropyrimidine-based treatment in the Brazilian Amazon. METHODS: The study population was composed of 216 patients, 92 of whom have an anatomopathological diagnosis of gastric cancer and 124 of colorectal cancer. The single nucleotide polymorphisms (SNP) were genotyped by allelic discrimination using the TaqMan OpenArray Genotyping technology, with a panel of 32 customized assays, run in a QuantStudio ™ 12K Flex Real-Time PCR System (Applied Biosystems, Life Technologies, Carlsbad USA). Ancestry analysis was performed using 61 autosomal ancestry informative markers (AIMs). RESULTS: The study population show mean values of 48.1% European, 31.1% Amerindian, and 20.8% African ancestries. A significant risk association for general and severe toxicity was found in the rs4451422 of FPGS (p = 0.001; OR 3.40; CI 95% 1.65-7.00 and p = 0.006; OR 4.63; CI 95% 1.56-13.72, respectively) and the rs9524885 of ABCC4 (p = 0.023; OR 2.74; CI 95% 1.14-6.65 and p = 0.024; OR 5.36; IC 95% 1.24-23.11, respectively) genes. The rs760370 in the SLC29A1 gene (p = 0.009; OR 6.71; CI 95% 1.16-8.21) and the rs1801133 in the MTHFR toxicity (p = 0.023; OR 3.09; CI 95% 1.16-8.21) gene also demonstrated to be significant, although only for severe toxicity. The results found in this study did not have statistics analysis correction. CONCLUSION: Four polymorphisms of the ABCC4, FPGS, SLC29A1, and MTHFR genes are likely to be potential predictive biomarkers for precision medicine in fluoropyrimidine-based treatments in the population of the Brazilian Amazon, which is constituted by a unique genetic background.


Assuntos
Protocolos de Quimioterapia Combinada Antineoplásica/farmacologia , Neoplasias Gastrointestinais/tratamento farmacológico , Neoplasias Gastrointestinais/genética , Protocolos de Quimioterapia Combinada Antineoplásica/efeitos adversos , Brasil , Camptotecina/análogos & derivados , Camptotecina/farmacologia , Transportador Equilibrativo 1 de Nucleosídeo/genética , Feminino , Fluoruracila/administração & dosagem , Fluoruracila/farmacocinética , Fluoruracila/farmacologia , Humanos , Leucovorina/farmacologia , Masculino , Metilenotetra-Hidrofolato Redutase (NADPH2)/genética , Pessoa de Meia-Idade , Proteínas Associadas à Resistência a Múltiplos Medicamentos/genética , Compostos Organoplatínicos/farmacologia , Peptídeo Sintases/genética , Variantes Farmacogenômicos , Polimorfismo de Nucleotídeo Único
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA